Otonomy Inc
F:7OT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Guangdong Hongjing Optoelectronic Technology Inc
SZSE:301479
|
CN |
|
I
|
Indo Asia Finance Ltd
BSE:530747
|
IN |
|
Ascendio Co Ltd
KRX:012170
|
KR |
|
A
|
Atlas Global Brands Inc
CNSX:ATL
|
CA |
|
Kinetiko Energy Ltd
ASX:KKO
|
AU |
|
F
|
FMS Enterprises Migun Ltd
TASE:FBRT
|
IL |
|
LS Electric Co Ltd
KRX:010120
|
KR |
|
U
|
Upbest Group Ltd
HKEX:335
|
HK |
Otonomy Inc
Research & Development
Otonomy Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Otonomy Inc
F:7OT
|
Research & Development
-$36.7m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$13.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Otonomy Inc
Glance View
Otonomy, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 51 full-time employees. The company went IPO on 2014-08-13. The firm is focused on the development of therapeutics for neurotology. The firm pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in in Phase II for tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in Phase IIa development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. OTO-825, a gene therapy for congenital hearing loss.
See Also
What is Otonomy Inc's Research & Development?
Research & Development
-36.7m
USD
Based on the financial report for Sep 30, 2022, Otonomy Inc's Research & Development amounts to -36.7m USD.
What is Otonomy Inc's Research & Development growth rate?
Research & Development CAGR 5Y
6%
Over the last year, the Research & Development growth was -17%. The average annual Research & Development growth rates for Otonomy Inc have been -1% over the past three years , 6% over the past five years .
